Cured of Hodgkin lymphoma, but suffering a broken heart

Leukemia and Lymphoma

Volumn 49, Issue 8, 2008, Pages 1433-1435

  Constine, Louis S ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

AGE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DISEASE SURVEILLANCE; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH CARE FACILITY; HEART INFARCTION; HODGKIN DISEASE; HOSPITALIZATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; METHODOLOGY; MULTIPLE CYCLE TREATMENT; NETHERLANDS; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COUNSELING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION SHIELD; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

ANTHRACYCLINES; CARDIOVASCULAR DISEASES; HODGKIN DISEASE; HUMANS; RISK FACTORS;

EID: 51349149962     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802238578     Document Type: Note

References (11)

1. Myrehaug, S., Pintilie, M., Tsang, R., Mackenzie, R., Crump, M. Chen, Z. et al. (2008) Cardiac morbidity following modern treatment for Hodgkin Lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma, 49, pp. 1485-1492.
2. Aleman, B. M., van den Belt-Dusebout, A W, De Bruin, M. L., van't Veer, M B, Baaijens, M. H. de Boer, J. P. et al. (2007) Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood, 109, pp. 1878-1863.
3. Hoppe, R. (1997) Hodgkin's disease: Complications of therapy and excess mortality. Ann Oncol, 8, pp. 115-118.
4. Mauch, P., Kalish, L. A. and Marcus, K. C. (1995) Long-term survival in Hodgkin's disease: Relative impact of mortality, second tumors, infection and cardiovascular disease. Cancer J Sci Am, 1, pp. 33-42.
5. Moser, E., Noordijk, E. van Leeuwen, F. et al. (2006) Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin's lymhoma. Blood, 107, pp. 2912-2929.
6. Ewer, M. and Lenihan, D. (2008) Left ventricular ejection fraction and cardiotoxicity: Is our ear really to the ground?. J Clin Onc, 26, pp. 1201-1203.
7. Swerdlow, A. J., Higgins, C. D., Smith, P., Cunningham, D., Hancock, B. W. Horwich, A. et al. (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study. J Natl Cancer Inst, 99, pp. 206-214.
8. Glanzmann, C., Kaufmann, P., Jenni, R., Hess, O. M. and Huguenin, P. (1998) Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol, 46, pp. 51-62.
9. Ferme, C., Eghbali, H., Meerwaldt, J. H., Rieux, C., Bosq, J. Berger, F. et al. (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med, 357, pp. 1916-1927.
10. Girinsky, T., van der Maazen, R., Specht, L., Aleman, B., Poortmans, P. Lievens, Y. et al. (2006) Involved node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines. Radiother Oncol, 79, pp. 270-277.
11. Zethelius, B., Berglund, L., Sundstrom, J., Ingelsson, E., Basu, S. Larsson, A. et al. (2008) Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med, 358, pp. 2107-2116.